Chairman and Founder
Mr. Chen is the Chairman and Founder of Clearbridge BioMedics.
Prior to founding Clearbridge, Mr. Chen worked at Pacific Century CyberWorks Limited, the incumbent and leading telecommunications company in Hong Kong. Mr. Chen is a member of the pioneering team at PCCW and was the President of CyberWorks Ventures, the Venture Capital and direct investment arm of PCCW. Mr. Chen was also the youngest member of PCCW’s Mergers Acquisitions executive committee, and was responsible for much of PCCW’s strategic expansion and many of its successful acquisitions and investments.
Mr. Chen has more than 12 years of entrepreneurship experience with start-ups, being the co-founder of 2 start-up companies with successful exits. Mr. Chen has also given talks on entrepreneurship in Hong Kong and the United States, including the Sloan School of Management at MIT. Mr. Chen is an active angel investor and was a member of the Hong Kong Science and Technology Park (HKSTP) incubator selection panel and a venture committee member of the Hong Kong Venture Capital and Private Equity Association (HKVCA). He is also currently a member of the Singapore NRF POC grant panel.
Mr. Chen is the recipient of the prestigious Sword of Honour from the Singapore Armed Forces, and holds a B.A., M.A. and M.Eng from the University of Cambridge, (U.K.).
Mr. Yee is the Executive Director and Chief Executive Officer of Clearbridge Health Limited, a healthcare company with a focus on the delivery of precision medicine in Asia. Mr. Yee founded CBMG (formerly known as Insight Medica Pte. Ltd.) in 2016 which is now part of the Clearbridge Health group.
Prior to founding CBMG, Mr. Yee was the chief executive officer from 2011-2016 of Cordlife Group Limited, a company listed on the SGX-ST, where he was responsible for identifying and implementing company-wide business growth strategies and organisational structures and overseeing all aspects of the group’s growth and operating functions.
Mr. Yee obtained his Bachelor of Arts in Economic and Social Studies from the Victoria University of Manchester in 1994, Master of Commerce (Finance with Banking/Management) from the University of Sydney in 1997, Bachelor of Commerce in Professional Accounting from the Murdoch University in 2009, Master of Business Administration from the Nanyang Technological University in 2011, Master of Business Administration from the University of Chicago Booth School of Business in 2012 and Master of Arts from the Columbia University in 2016.
Mr. Yee completed the UC Berkeley – Nanyang Advanced Management Program in 2009/2010. He also received the Furama Ltd Endowed Book Prize from the Nanyang Technological University in 2011.
Mr. Qian was the vice president, the director of public affairs and the secretary of the Board of Trauson Holdings Company Limited. Mr. Qian graduated from Simon Fraser University in Canada with both BBA and MBA degrees. He is now a registered senior economist. He serves as a member of Changzhou Municipal Chinese People’s Political Consultative Conference (CPPCC). Mr. Qian brings with him a wealth of experience in IPO and M&A, where he was responsible for project coordination and legal affairs, along with corporate re-organisation.
Dr Juanita FU
Dr. Fu is a General Partner of Bioveda Capital, a venture capital firm focused exclusively on investments in healthcare and biotechnology.
She has more than ten years of clinical experience with a focus on internal medicine, and has practiced in the Singapore General Hospital, National University Hospital and in a group practice in the United States. She does investments through a family office in Kuo International Pte Ltd and is a director of Kuo Investments Ltd. In her own personal capacity, she does angel investments in early start-up companies.
Dr. Fu received her B.S. in Biology from Columbia University, New York and her M.D. from the University of Southern California. She is certified with the American Board of Internal Medicine and is also a registered physician with the Singapore Medical Council.
Nicolas H. ROELOFS, PhD
Dr. Roelofs served as Senior Vice President at Agilent Technologies Inc., as well as President of its Life Sciences Group from 2009 to 2013. He also served as the Vice President and General Manager of the Life Sciences division from 2006 to 2009. His contributions during his term at Agilent Technologies Inc., in the areas of business development, sales, manufacturing, R&D and marketing saw him play a key role in the life science business.
Prior to joining Agilent Technologies Inc., Dr. Roelofs was with Bio-Rad Laboratories, Inc., from 2005 to 2006 and served as the Life Science Group’s Group Operations Officer heading five business divisions spanning life science and food science. His time at Stratagene Corporation from 2001 to 2005 saw him serve as Senior Vice President of marketing, sales and business development for the first 2 years and as Chief Operating Officer for the last 2 years.
Professionally, Dr. Roelofs is a Global 50 Member and also a part of the Malaysian Biotechnology International Advisory Panel. He also serves on the Advisory Board of Chemical & Engineering News for the American Chemical Society Magazine from 2010 to 2013. Dr. Roelofs completed his M.S. in Organic Chemistry from Iowa State University following which he completed his PhD in Organic Chemistry from the University of Nevada, Reno.
Prof. Chwee Teck LIM
Advisor and Founder
Professor Lim currently holds joint appointments at both the Departments of Bioengineering and Mechanical Engineering at the National University of Singapore (NUS). He is also a Principal Investigator at the Mechanobiology Institute as well as a Faculty Fellow of the Singapore-MIT Alliance Center for Science & Technology. Professor Lim heads the Nano Biomechanics Lab which conducts basic and applied research in the mechanobiology of human diseases as well as the development of microfluidic biochips for the detection and diagnosis of cancer.
Prof. Lim has published more than 200 peer-reviewed journal papers (including over 30 invited/review articles and 12 ISI highly cited papers), 20 book chapters and delivered more than 200 plenary/keynote/invited talks. He is currently on the editorial boards of 11 international journals. Prof. Lim is also a Council Member of the World Council for Biomechanics. He has co-founded 3 start-ups that exploit inventions that he has developed in his lab.
Prof. Lim and his team have won several research awards and honors including the Wall Street Journal Asian Innovation Award (Gold) 2012, Credit Suisse Technopreneur of the Year Award 2012, TechVenture Most Disruptive Innovation Award 2012, Asian Entrepreneurship Award (First Prize) 2012, President’s Technology Award 2011, Faculty Research Award 2011, IES Prestigious Engineering Achievement Award 2010, Tan Kah Kee Young Inventor’s Award 2009, highly cited author award as well as Best Paper and Best Poster awards in international conferences. His research was cited by the MIT Technology Review magazine as one of the top ten emerging technologies of 2006 that will “have a significant impact on business, medicine or culture”.
Prof. XIE Tian, MD, PhD
Professor Xie is currently Dean of the Holistic Integrative Oncology Institutes, Director of the Integrative Cancer Center of Chinese and Western Medicine, Dean of the Holistic Integrative Pharmacy Institutes, Director of the Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, and Director of the Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University.
Prof. Xie was honoured with first class of the Science and Technology Progress Award of Ministry of Education in 2008, first class of the Science and Technology Award of China Society of Integrated Traditional Chinese and Western Medicine in 2009, second class of the National Science and Technology Progress Award in 2012, the China Outstanding Invention Patent Award in 2013, the Wu Jieping Medical Innovation Award in 2014, the Science and Technology Innovation Award of Ho Leung Ho Lee in 2016, and the Special Contribution Award for Science and Technology Innovation of Hangzhou city in 2017. He also obtained a fund from the Key Program of National Natural Science Foundation in 2017.
Prof. Xie innovatively proposed a new concept for the development of drugs based on the theory of integrated Chinese and Western medicine and “molecular compatibility”. Under the guidance of the theory, he led the team to discover the anti-cancer natural active ingredient of Elemene with high efficiency and low toxicity from Wenyujin which is one of the “Zhebawei” medicinal herbs, pioneered the application of liposomal targeted drug delivery system to the new drug development of Elemene, successfully developed new anti-cancer drugs with multiple targets and “two-way anticancer” effects including Elemene injection (liposomes) and Elemene oral emulsion (liposomes), and set a precedent for the treatment of cancer by small molecule terpenoids.
Jonathan Liau joined the Clearbridge Health Limited Group as Chief Commercial Officer in August 2017 and is responsible for overseeing the commercial strategy and development of the Group.
From June 2004 to October 2004, he was a process engineer with Amigo Pharma Consulting Pte. Ltd. where he was responsible for the design of process engineering solutions for pharmaceutical and biopharmaceutical projects. From 2004 to 2013, he was with Cordlife Services (S) Pte. Ltd.(now known as Life Corporation Services (S) Pte. Ltd.), where his last held position was chief operating officer and was responsible for the overall operations of the company.
From 2013 to 2016, he was a senior director of corporate development at Cordlife Group Limited, a company listed on the SGX-ST. He was responsible for corporate development, new products and general management responsibilities in several of the group’s subsidiaries.
From 2016 to 2017, he was a vice president (investments) at EDBI Pte. Ltd., the corporate investment arm of the Singapore Economic Development Board, where he led investments and oversaw portfolio management in the medical technology and biopharmaceutical fields.
Jonathan Liau graduated with a Master of Biochemical Engineering with Bioprocess Management from the University College London in 2004 and a Master of Business Administration from the University of Chicago in 2013.
Ali Asgar BHAGAT, PhD
Scientific and Technical Advisor
Ali, Scientific and Technical Advisor of Clearbridge Biomedics is the inventor of the ‘Dean Flow Fractionation’ cell separation concept. He leads the design and development of our ClearCell® line of products and CTChips®. Inventor on 4 granted patents and author of over 30 peer-reviewed scientific publications, Ali’s interests lie in developing technologies and products, building teams, and taking a concept from prototype to commercial launch and revenue.
Ali received his MS (2006) and PhD (2009) in Electrical Engineering from the University of Cincinnati, USA. Following his degree, he held Associate Scientist position at Massachusetts Institute of Technology (MIT), USA. Before joining Clearbridge, Ali worked as a Research Scientist in the newly formed Biosystems and Micromechanics (BioSyM) group at the Singapore-MIT Alliance for Research and Technology (SMART) Centre, Singapore.
Wei Chee TAN
Wei Chee, Finance Controller who leads the Finance and Human Resource functions in Clearbridge BioMedics. As a Financial Controller, he oversees financial and management accounting, funding and capital management, as well as recruiting.
He is also a member of Institute of Singapore Chartered Accountants (ISCA) and previously served as an Audit Manager at Deloitte & Touche prior to joining Clearbridge BioMedics.
Wei Chee graduated with Bachelor in Accountancy from Nanyang Business School (Nanyang Technological University).
Chief Operating Officer
Junquan leads design translation and product commercialisation for Clearbridge BioMedics. He directs product design, engineering and software development initiatives to meet both commercially-ready products and international regulatory standards, relevant to clinicians and pathology laboratories dedicated to cancer diagnostics.
He previously served as a Regulatory Specialist at Health Sciences Authority, consulting and training several medical technology companies seeking regulatory approvals in safety and performance of their medical devices. Prior to his regulatory role, serving in the A*Star Biomedical Research Council, he managed the establishment of Lonza’s cell therapy facility in Singapore. During his stint at St Vincent’s Institute in Melbourne, he led a team of researchers to successfully isolate islets and achieve the first human islet transplantation in Victoria, Australia.
Junquan graduated with Bachelors with First Class Honours in Immunology and Pharmacology from the University of Melbourne, Australia.